Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Stomach Cancer Market Insights, Trends and Innovations Worldwide, 2026-2030 & 2035

globenewswire.com
PFE Pfizer Inc. is mentioned as a major contributor to the stomach cancer market, indicating its involvement in this growing sector. The article does not provide specific performance data or outlook for Pfizer. MRK Merck & Co. is listed as a key player in the stomach cancer market. The article highlights the market's growth and innovation, implying Merck's participation, but offers no specific sentiment or performance details. SNY Sanofi S.A. is identified as a major contributor to the stomach cancer market. The article focuses on market growth and trends, suggesting Sanofi's involvement, but lacks specific sentiment or performance analysis for the company. BMY Bristol Myers Squibb is named as a significant contributor to the stomach cancer market. The article discusses market expansion and innovation, implying the company's role, but does not offer specific sentiment or performance insights. AZN AstraZeneca is mentioned as a major contributor in the stomach cancer market. The article details market growth and therapeutic advancements, suggesting AstraZeneca's participation, but provides no specific sentiment or performance indicators. NVS Novartis is listed as a key player in the stomach cancer market. The article discusses the market's growth and innovation, implying Novartis's involvement, but does not offer specific sentiment or performance analysis for the company. ASRT Astellas Pharma is highlighted for launching Vyloy (zolbetuximab-clzb) in October 2024, a targeted therapy for CLDN18.2-positive tumors. This innovation in a growing market suggests positive momentum and potential for improved patient outcomes. GSK GSK plc. is noted for amplifying its oncology portfolio by acquiring IDRx, Inc. for USD 1.15 billion to advance targeted cancer therapies. This strategic acquisition in a growing market indicates a positive outlook and commitment to oncology innovation.

Stomach Cancer Market Insights, Trends and Innovations Worldwide, 2026-2030 & 2035 Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Stomach Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. This report provides insights into market dynamics, trends, opportunities, and regional and competitor analyses.

The stomach cancer market is witnessing substantial growth, with a projected increase from USD 3.74 billion in 2025 to USD 4.26 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.9%. This expansion is due to the rising incidence of gastric cancer globally, the prevalence of Helicobacter pylori infections, the enhanced use of chemotherapy, and improvements in oncology infrastructure and diagnostic imaging techniques.

By 2030, the market is anticipated to reach USD 7.14 billion, with a CAGR of 13.8%, driven by the adoption of precision oncology and investments in novel biologics and immunotherapy pipelines.

The Helicobacter pylori infection contributes to market growth by inducing chronic inflammation that increases cancer risk. The infection's rising prevalence, exacerbated by inadequate sanitation and living conditions, fuels market expansion. As reported by the Government of Canada, the recurrence rate of this infection stood at 19% in 2023.

Key industry players are innovating with therapies like claudin (CLDN18.2)-targeted cytolytic antibody solutions to enhance treatment precision for HER2-negative gastric cancers. In October 2024, Astellas Pharma launched Vyloy (zolbetuximab-clzb), targeting CLDN18.2-positive tumors to amplify survival rates with reduced toxicity when used alongside chemotherapy. Similarly, GSK plc. amplified its oncology portfolio by acquiring IDRx, Inc. for USD 1.15 billion to advance targeted cancer therapies.

Major contributors in the market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Sanofi S.A., Bristol Myers Squibb, AstraZeneca, Novartis, and others. Regionally, North America led the market in 2025, while the Asia-Pacific region is set for the fastest growth moving forward. Countries covered in this context span Australia, China, Germany, India, Japan, the UK, the USA, among others.

Reasons to Purchase:

Report Scope

Markets Covered:

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Regions: Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Data Segmentation: Country and regional analysis with competitor market shares.

Key Attributes

The companies featured in this Stomach Cancer market report include:

For more information about this report visit https://www.researchandmarkets.com/r/hheo5h

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment